Literature DB >> 22248522

Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma.

Harun Fajkovic1, Eugene K Cha, Claudio Jeldres, Gerhard Donner, Thomas F Chromecki, Vitaly Margulis, Giacomo Novara, Yair Lotan, Jay D Raman, Wassim Kassouf, Christian Seitz, Karim Bensalah, Alon Weizer, Eiji Kikuchi, Marco Roscigno, Mesut Remzi, Kazumasa Matsumoto, Eckart Breinl, Armin Pycha, Vincenzo Ficarra, Francesco Montorsi, Pierre I Karakiewicz, Douglas S Scherr, Shahrokh F Shariat.   

Abstract

PURPOSE: We assessed the prognostic value of extranodal extension and other lymph node parameters in a large multicenter cohort of patients with lymph node metastasis after radical nephroureterectomy.
MATERIALS AND METHODS: We retrospectively analyzed the records of 222 patients with lymph node metastasis treated with radical nephroureterectomy for upper tract urothelial carcinoma without neoadjuvant therapy. Each lymph node metastasis was microscopically evaluated for extranodal extension.
RESULTS: A median of 4 lymph nodes (IQR 8) was removed. Two lymph nodes (IQR 2) were positive. Lymph node density was 51.3% (IQR 71.7%). Overall 110 patients (49.5%) had extranodal extension, which was associated with more advanced pT stage (p = 0.026). On multivariable analysis extranodal extension was associated with disease recurrence (p = 0.01) and cancer specific mortality (p = 0.013). When stratified by a 30% cutoff, lymph node density was associated with disease recurrence and cancer specific mortality on univariable but not multivariable analysis (p = 0.048 and 0.049, respectively). Adding extranodal extension to a multivariable model including pT stage and tumor architecture improved predictive accuracy for disease recurrence from 70.3% to 74.5% (p <0.001). Adding extranodal extension to a multivariable model including age, pT stage and tumor architecture improved predictive accuracy for cancer specific mortality from 70.6% to 74.4% (p <0.001).
CONCLUSIONS: Extranodal extension is a powerful predictor of clinical outcomes in patients with upper tract urothelial carcinoma with lymph node metastasis. While other lymph node parameters seem to have limited clinical value, extranodal extension could help risk stratify patients with upper tract urothelial carcinoma and lymph node metastasis for better counseling and clinical trial design.
Copyright © 2012 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22248522     DOI: 10.1016/j.juro.2011.10.158

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  15 in total

1.  Association between lymph node yield and survival among patients undergoing radical nephroureterectomy for urothelial carcinoma of the upper tract.

Authors:  Piotr Zareba; Barak Rosenzweig; Andrew G Winer; Jonathan A Coleman
Journal:  Cancer       Date:  2017-02-02       Impact factor: 6.860

Review 2.  Predictive tools for clinical decision-making and counseling of patients with upper tract urothelial carcinoma.

Authors:  Evanguelos Xylinas; Luis Kluth; Sibani Mangal; Morgan Roupret; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  World J Urol       Date:  2012-09-18       Impact factor: 4.226

3.  [Elective organ and function preservation in ureter and renal pelvis tumors].

Authors:  S Rausch; G Gakis; J Bedke; A Stenzl
Journal:  Urologe A       Date:  2014-09       Impact factor: 0.639

4.  Preoperative hydronephrosis as a predictor of postnephroureterectomy survival in patients with upper tract urothelial carcinoma: a two-center study in Japan.

Authors:  Tomohiro Fukui; Toru Kanno; Go Kobori; Seiji Moroi; Hitoshi Yamada
Journal:  Int J Clin Oncol       Date:  2019-09-03       Impact factor: 3.402

5.  The Value of Lymph Node Dissection in Patients With Node-Positive Upper Urinary Tract Urothelial Cancer: A Retrospective Cohort Study.

Authors:  Hao-Ran Xia; Shu-Guang Li; Xing-Quan Zhai; Min Liu; Xiao-Xiao Guo; Jian-Ye Wang
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

6.  The impact of lymph node status and features on oncological outcomes in urothelial carcinoma of the upper urinary tract (UTUC) treated by nephroureterectomy.

Authors:  Adil Ouzzane; Pierre Colin; Tarek P Ghoneim; Marc Zerbib; Alexandre De La Taille; François Audenet; Fabien Saint; Nicolas Hoarau; Emilie Adam; Marie Dominique Azemar; Henri Bensadoun; Luc Cormier; Olivier Cussenot; Alain Houlgatte; Gilles Karsenty; Charlotte Maurin; François Xavier Nouhaud; Véronique Phe; Thomas Polguer; Mathieu Roumiguié; Alain Ruffion; Morgan Rouprêt
Journal:  World J Urol       Date:  2012-12-11       Impact factor: 4.226

7.  Current Status of Lymphadenectomy During Radical Nephroureterectomy for Upper Tract Urothelial Cancer-Yes, No or Maybe?

Authors:  Ashwin Sunil Tamhankar; Saurabh Ramesh Patil; Puneet Ahluwalia; Gagan Gautam
Journal:  Indian J Surg Oncol       Date:  2018-08-13

Review 8.  The role of systemic chemotherapy in management of upper tract urothelial cancer.

Authors:  Bishoy A Gayed; Gregory R Thoreson; Vitaly Margulis
Journal:  Curr Urol Rep       Date:  2013-04       Impact factor: 3.092

Review 9.  Contemporary role of lymph node dissection at the time of radical nephroureterectomy for upper tract urothelial carcinoma.

Authors:  Thomas Seisen; Shahrokh F Shariat; Olivier Cussenot; Benoit Peyronnet; Raphaële Renard-Penna; Pierre Colin; Morgan Rouprêt
Journal:  World J Urol       Date:  2016-01-25       Impact factor: 4.226

Review 10.  Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma.

Authors:  Victor M Schuettfort; Benjamin Pradere; Fahad Quhal; Hadi Mostafaei; Ekaterina Laukhtina; Keiichiro Mori; Reza Sari Motlagh; Michael Rink; David D'Andrea; Mohammad Abufaraj; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  Turk J Urol       Date:  2020-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.